|
|
Sight Sciences Inc (NASDAQ: SGHT) |
|
Price: $8.3500
$-0.03 
-0.358%
|
| Day's High:
| $8.449999809265137
| Week Perf:
| -1.76 %
|
| Day's Low: |
$ 8.14 |
30 Day Perf: |
17.77 % |
| Volume (M): |
102,466 |
52 Wk High: |
$ 9.24 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$5.56 |
| Open: |
$8.27 |
52 Wk Low: |
$3.19 |
|
|
| Market Capitalization (Millions $) |
450 |
| Shares
Outstanding (Millions) |
54 |
| Employees |
186 |
| Revenues (TTM) (Millions $) |
79 |
| Net Income (TTM) (Millions $) |
-37 |
| Cash Flow (TTM) (Millions $) |
-24 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Sight Sciences Inc. is a medical technology company focused on designing and developing non-surgical treatments for patients with vision-threatening eye diseases. The company's primary aim is to improve surgical outcomes and enhance patient quality of life through innovative and minimally invasive solutions. Its products include the OMNI Surgical System, a comprehensive platform for the treatment of glaucoma, as well as the TearCare System, which provides a novel approach to treating evaporative dry eye. Sight Sciences Inc. is known for its commitment to advancing ophthalmic care and addressing unmet needs in the field.
Company Address: 4040 Campbell Ave Menlo Park 94025 CA
Company Phone Number: 266-1144 Stock Exchange / Ticker: NASDAQ SGHT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Mon, Oct 20 2025 11:12 AM UTC
Sight Sciences Announces Medicare Fee Schedule for TearCare Procedure, Enhancing Access to Interventional Dry Eye Treatment MENLO PARK, Calif., Oct. 17, 2025 Sight Sciences, Inc. (Nasdaq: SGHT), a pioneering eyecare technology company dedicated to revolutionizing the treatment landscape for eye-related conditions, has made significant strides in patient care by announci...
|
| Announcement
Published Thu, Dec 19 2024 9:05 PM UTC
Cost-Effective Innovations in Ocular Health: Budget Impact Analysis of Sight Sciences’ TearCare System for Meibomian Gland DiseaseThe field of ophthalmology is on the cusp of transformation with the innovative introduction of the TearCare System by Sight Sciences, designed specifically for the treatment of Meibomian Gland Disease (MGD). As the prevalence of MGD continues ...
|
| Management Changes
Published Thu, Nov 7 2024 9:04 PM UTC
In a notable shift aimed at reinvigorating its strategic direction, Sight Sciences Inc. has recently appointed MK Raheja as Executive Vice President of Research and Development, and Brenton Taylor as Executive Vice President of Operations. These appointments signal the company’s renewed commitment to innovating in the eyecare landscape, particularly in light of the stagge...
|
| Clinical Study
Published Mon, Oct 14 2024 8:05 PM UTC
Dry eye disease (DED) remains a significant public health concern, impacting the quality of life of individuals globally. Recent advancements in treatment options, particularly investigator-initiated clinical trials involving TearCare, present a promising outlook for enhanced patient outcomes. However, these clinical successes occur against a backdrop of ongoing financial ch...
|
| Announcement
Published Thu, Aug 1 2024 8:06 PM UTC
Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance MENLO PARK, Calif., Aug. 01, 2024 Sight Sciences, Inc. (Nasdaq: SGHT), a pioneering eyecare technology company, has released its financial results for the second quarter ended June 30, 2024. The company is dedicated to developing and commercializing innovative inte...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.71 $ |
| Revenues (TTM) |
1.46 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.58 $
|
| Book Value |
1 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
422,312 |
| Net
Income per Employee (TTM) |
-200,280 |
| Receivable Turnover Ratio (TTM) |
7.91 |
| Inventory Turnover Ratio (TTM) |
1.38 |
| Asset Turnover Ratio (TTM) |
0.68 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.71 $
|
| Revenues (TTM) |
1.46 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.58 $
|
| Book Value |
1 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Interventional Glaucoma |
|
 96.66 % |
of total Revenue |
| Interventional Dry Eye |
|
7.13 % |
of total Revenue |
| |
On March 5 2025 the Sight Sciences Inc provided following guidance
nnSight Sciences Inc. Reports Q4 and Full Year 2024 Financial Outcomes and Introduces Guidance for 2025nn
nnMENLO PARK, Calif., March 5, 2025nn — Sight Sciences, Inc. (Nasdaq: SGHT), a leading eyecare technology firm dedicated to the development and commercialization of groundbreaking, interventional solutions aimed at enhancing the standard of care in eye care, has announced its financial results for the fourth quarter and the complete year ending December 31, 2024. In addition, the company has outlined its financial outlook for the entire year of 2025.
While specific details regarding the 2025 financial guidance were not explicitly mentioned in the announcement, the company’s report r...
|
|
|
0.38%